Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain.
Knobel H, Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Palacios R, Antela A, Blanco JR, Fulladosa X, Refollo E; VACH Cohort. Knobel H, et al. Among authors: suarez lozano i. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun-Jul;37(6):373-379. doi: 10.1016/j.eimc.2018.09.015. Epub 2018 Oct 30. Enferm Infecc Microbiol Clin (Engl Ed). 2019. PMID: 30389268 English, Spanish.
Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study.
Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Knobel H, Palacios R, Antela A, Blanco JR, Fulladosa X; VACH. Domingo P, et al. Among authors: suarez lozano i. Nefrologia (Engl Ed). 2019 Sep-Oct;39(5):497-505. doi: 10.1016/j.nefro.2019.01.009. Epub 2019 Apr 24. Nefrologia (Engl Ed). 2019. PMID: 31027896 Free article. English, Spanish.
Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
Pérez-Molina JA, Suárez-Lozano I, Del Arco A, Teira R, Bachiller P, Pedrol E, Martínez-Alfaro E, Domingo P, Mariño A, Ribera E, Antela A, de Otero J, Navarro V, González-García J; Gesida 5808 Study Group. Pérez-Molina JA, et al. HIV Clin Trials. 2011 Jan-Feb;12(1):1-8. doi: 10.1310/hct1201-1. HIV Clin Trials. 2011. PMID: 21388936
[Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)].
Teira R, Suárez-Lozano I, Muñoz P, Viciana P, Lozano F, Galindo MJ, Terrón A, Vergara A, Geijo P, Arribas JR, Cosín J, Domingo P, Ribera E, Roca B, García-Alcalde ML, Sánchez T, Muñoz-Sanz A. Teira R, et al. Enferm Infecc Microbiol Clin. 2005 Apr;23(4):213-7. doi: 10.1157/13073147. Enferm Infecc Microbiol Clin. 2005. PMID: 15826546 Spanish.
Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I. Estrada V, et al. BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36. BMC Womens Health. 2011. PMID: 21816091 Free PMC article.
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sanchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I; VACH Study Group. Teira R, et al. Among authors: suarez lozano i. HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1. HIV Med. 2017. PMID: 27476742 Free article.
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group. Perez-Molina JA, et al. Among authors: suarez lozano i. J Antimicrob Chemother. 2017 Jan;72(1):246-253. doi: 10.1093/jac/dkw379. Epub 2016 Sep 13. J Antimicrob Chemother. 2017. PMID: 27629070 Free article. Clinical Trial.
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
39 results